Literature DB >> 17125210

Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling.

Peter S Bazeley1, Sridevi Prithivi, Craig A Struble, Richard J Povinelli, Daniel S Sem.   

Abstract

Cytochrome P450 2D6 (CYP2D6) is used to develop an approach for predicting affinity and relevant binding conformation(s) for highly flexible binding sites. The approach combines the use of docking scores and compound properties as attributes in building a neural network (NN) model. It begins by identifying segments of CYP2D6 that are important for binding specificity, based on structural variability among diverse CYP enzymes. A family of distinct, low-energy conformations of CYP2D6 are generated using simulated annealing (SA) and a collection of 82 compounds with known CYP2D6 affinities are docked. Interestingly, docking poses are observed on the backside of the heme as well as in the known active site. Docking scores for the active site binders, along with compound-specific attributes, are used to train a neural network model to properly bin compounds as strong binders, moderate binders, or nonbinders. Attribute selection is used to preselect the most important scores and compound-specific attributes for the model. A prediction accuracy of 85+/-6% is achieved. Dominant attributes include docking scores for three of the 20 conformations in the ensemble as well as the compound's formal charge, number of aromatic rings, and AlogP. Although compound properties were highly predictive attributes (12% improvement over baseline) in the NN-based prediction of CYP2D6 binders, their combined use with docking score attributes is synergistic (net increase of 23% above baseline). Beyond prediction of affinity, attribute selection provides a way to identify the most relevant protein conformation(s), in terms of binding competence. In the case of CYP2D6, three out of the ensemble of 20 SA-generated structures are found to be the most predictive for binding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17125210     DOI: 10.1021/ci600267k

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  7 in total

Review 1.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

2.  CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.

Authors:  M Ramesh; Prasad V Bharatam
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

3.  RS-predictor: a new tool for predicting sites of cytochrome P450-mediated metabolism applied to CYP 3A4.

Authors:  Jed Zaretzki; Charles Bergeron; Patrik Rydberg; Tao-wei Huang; Kristin P Bennett; Curt M Breneman
Journal:  J Chem Inf Model       Date:  2011-06-15       Impact factor: 4.956

4.  Sterol carrier protein-2: binding protein for endocannabinoids.

Authors:  Elizabeth Sabens Liedhegner; Caleb D Vogt; Daniel S Sem; Christopher W Cunningham; Cecilia J Hillard
Journal:  Mol Neurobiol       Date:  2014-02-09       Impact factor: 5.590

Review 5.  Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.

Authors:  Johannes Kirchmair; Mark J Williamson; Jonathan D Tyzack; Lu Tan; Peter J Bond; Andreas Bender; Robert C Glen
Journal:  J Chem Inf Model       Date:  2012-02-17       Impact factor: 4.956

6.  A Novel Scoring Based Distributed Protein Docking Application to Improve Enrichment.

Authors:  Prachi Pradeep; Craig Struble; Terrence Neumann; Daniel S Sem; Stephen J Merrill
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2015 Nov-Dec       Impact factor: 3.710

7.  CYP 2D6 binding affinity predictions using multiple ligand and protein conformations.

Authors:  Lovorka Perić-Hassler; Eva Stjernschantz; Chris Oostenbrink; Daan P Geerke
Journal:  Int J Mol Sci       Date:  2013-12-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.